What it is
Hexarelin is a synthetic growth hormone secretagogue (GHSR-1a agonist) with a distinctive additional property: it also binds the CD36 scavenger receptor, giving it GH-independent cardioprotective effects in preclinical ischemia-reperfusion models. It is among the most potent secretagogues in the GHRP family.
Evidence boundary
Phase 2 clinical study exists (GH stimulation, cardiac); research use is limited to laboratory and education contexts.
Trial evidence
- Hexarelin has been studied in Phase 2 clinical trials for GH stimulation and in preclinical ischemia-reperfusion models for its CD36-mediated cardioprotective action.
Preparation and measurement
Reconstitution: 2 mg vial + 2 mL BAC = 1 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Conservative start | 100 mcg | 10 U (0.1 mL) | 2× daily | 1.4 mg/week |
| Standard research | 150 mcg | 15 U (0.15 mL) | 2–3× daily | 2.1–3.15 mg/week |
| Advanced research | 200 mcg | 20 U (0.2 mL) | 2–3× daily | 2.8–4.2 mg/week |
Conservative start
- Dose
- 100 mcg
- Draw / measure
- 10 U (0.1 mL)
- Frequency
- 2× daily
- Weekly total
- 1.4 mg/week
Standard research
- Dose
- 150 mcg
- Draw / measure
- 15 U (0.15 mL)
- Frequency
- 2–3× daily
- Weekly total
- 2.1–3.15 mg/week
Advanced research
- Dose
- 200 mcg
- Draw / measure
- 20 U (0.2 mL)
- Frequency
- 2–3× daily
- Weekly total
- 2.8–4.2 mg/week
Weekly totals apply only during the active phase.
Titration rules
- Common range: 100–200 mcg per injection, 2–3 times daily.
- Desensitization occurs within 1–2 weeks of continuous use — hexarelin is typically run 8–12 weeks then 4 weeks off.
- Start at 100 mcg to assess tolerance, move to 150–200 mcg after a few days.
- Rotate injection sites; do not co-mix with other peptides in the same syringe unless compatibility is confirmed.